TYR and neoplasm: Current DC vaccination trials with melanoma patients use different types of tumor-associated Ags for loading of DCs for vaccination such as tumor lysate, tumor cell mRNA and several non-mutated self-Ags (e.g., gp100, MART1, tyrosinase) [16].